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Abstract
Tumors grown in a stroma-rich mouse model resembling clinically advanced bladder carcinoma
with UMUC3 and NIH 3T3 cells have high levels of fibroblasts and an accelerated tumor growth
rate. We used this model to investigate the synergistic effect of combined gemcitabine
monophosphate (GMP) nanoparticles and Cisplatin nanoparticles (Combo NP) on tumor-
associated fibroblasts (TAFs). A single injection of Combo NP had synergistic anti-tumor effects
while the same molar ratio of combined GMP and Cisplatin delivered as free drug (Combo Free)
fell outside of the synergistic range. Combo NP nearly halted tumor growth with little evidence of
general toxicity while Combo Free had only a modest inhibitory effect at 16 mg/kg GMP and 1.6
mg/kg Cisplatin. Combo NP increased levels of apoptosis within the tumor by approximately 1.3
fold (TUNEL analysis) and decreased α-SMA-positive fibroblast recruitment by more than 87%
(immunofluorescence) after multiple injections compared with Combo Free, GMP NP or Cisplatin
NP alone. The TAF-targeting capability of Combo NP was evaluated by double staining for
TUNEL and α-SMA at various time points after a single injection. On day one after injection,
57% of the TUNEL-positive cells were identified as α-SMA-positive fibroblasts. By day four,
tumor stroma was 85% depleted and 87% of the remaining TAFs were TUNEL-positive. Combo
NP-treated tumors became 2.75 fold more permeable than those treated with Combo Free as
measured by Evans Blue. We conclude that the antineoplastic effect of Combo NP works by first
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targeting TAFs and is more effective as an anti-tumor therapy than Combo Free, GMP NP or
Cisplatin NP alone.
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1. Introduction
Bladder cancer, the fourth most common cancer diagnosed in men and the eighth in women,
remains a concern due to its prevalence and tendency to progress and recur [1–3]. Advances
in drug delivery are needed and nanomedicine in particular holds promise as a means to
improve bioavailability and half-life in circulation [4,5]. These therapies make use of the
enhanced permeability and retention (EPR) effect in tumors, thereby increasing the
chemotherapeutic dose to tumor tissue, while at the same time sparing normal tissue from
exposure [6]. Improved drug uptake by tumor cells will also be an important consideration
to achieve higher bioavailability.
Cancer has long been believed to be cell-autonomous and to date most research has focused
directly on the malignant cells themselves. New data, however, suggests that carcinogenesis
is determined not only by malignant cells, but also by a favorable tumor microenvironment
[7]. Fibroblasts are the principal cellular component of the tumor microenvironment.
Fibroblasts that have been recruited, activated and accumulated in close proximity to the
tumor are referred to as tumor-associated fibroblasts (TAFs), myofibroblasts, or cancer-
associated fibroblasts. In some instances, TAFs can be the most abundant type of cell within
some tumors, notably pancreatic and breast carcinoma [8,9]. These cells are characterized by
high expression of α-smooth muscle actin (α-SMA). They contribute to tumor growth and
invasiveness by remodeling the extracellular matrix, secreting various soluble factors
(growth factors and cytokines), and suppressing immune responses. Normalization or
elimination of activated stroma should be considered as a potential approach to anti-cancer
therapy [10]. Therapies directed at TAFs can be divided into four categories: (1) inhibition
of stromal cell proliferation; (2) interference with growth factor/cytokine-mediated signals
between TAFs and cancer cells [11]; (3) targeting of epigenetic alterations (DNA
methylation); (4) modification of the inflammatory response [12].
Myofibroblasts tend to be present in invasive bladder tumors and may be an individual
prognostic factor in urothelial carcinoma [13]. To identify and test TAF-targeting drugs for
treatment of bladder cancer, a model system is needed which reproduces the stroma-rich
tumor growth observed in patients. Human tumor xenografts in immunodeficient mice are
often used for preclinical studies of anti-cancer agents. A subcutaneous xenograft is most
commonly used due to ease of implanting tumor cells and unobstructed access to the tumor.
A major criticism of this model, however, is that the local environment may not adequately
simulate the carcinoma microenvironment [14]. Here we report the establishment of a
stroma-rich, subcutaneous xenograft tumor model. Fibroblasts were subcutaneously co-
injected along with cancerous cells and Matrigel, a permissive extracellular matrix
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preparation. When grown on Matrigel in vivo, bladder carcinoma cells adopt a more
characteristic phenotype [15] and the xenograft better resembles the original tumor when
compared to the more commonly used model.
We recently developed nanoparticles for treatment of non-small-cell lung cancer that
encapsulate gemcitabine monophosphate (GMP, the bioactive form of gemcitabine) [16].
We have also developed Cisplatin nanoparticles by mixing the highly soluble precursor cis-
diaminodihydroplatinum (II) with KCl [17]. In both cases, high drug entrapment efficiency
was achieved with NP diameters of approximately 45 nm and 40 nm for GMP NP and
Cisplatin NP, respectively.
Our current work aimed to develop a stroma-rich, subcutaneous xenograft bladder tumor
model for evaluation of TAF-targeting anti-tumor drugs. We planned to use this model
system to evaluate GMP NP and Cisplatin NP combination therapy (Combo NP) in terms of
delivery, accumulation of drug within the tumor, and anti-tumor activity. We also set out to
investigate the TAF-targeting capability of Combo NP with TAFs apoptosis, collagen
deposition and changes in tumor permeability evaluated.
2. Materials and Methods
2.1. Materials
Gemcitabine monophosphate disodium salt (GMP, purity≥97%) was provided by Qualiber,
Inc. (Chapel Hill, NC). Cisplatin (cis-diamminedichloroplatinum (II)) was purchased from
Sigma-Aldrich (Dorset, UK). GMP NP (including 3H-labeled GMP NP) and Cisplatin NP
were prepared as described previously [16,17]. Size distribution and zeta potential were
measured on a Malvern ZetaSizer Nano series (Westborough, MA).
The human bladder transitional cell line UMUC3 was from the American Type Culture
Collection (ATCC), and the mouse embryonic fibroblast cell line NIH 3T3 (UNC Tissue
Culture Facility) were cultured in Dulbecco’s modified Eagle’s Media (DMEM) (Invitrogen,
Carlsbad, CA) supplemented with penicillin (100 U/mL) and streptomycin (100 µg/mL)
(Invitrogen), and 10% fetal bovine serum (Sigma, St. Louis, MO)/10% Bovine calf serum
(Hyclone, Logan, Utah), respectively. Cells were cultivated in a humidified incubator at 37
°C and 5% CO2 and harvested with 0.05% trypsin-EDTA before subculture.
Female nude mice 6–8 weeks of age were used in all studies. All work performed on
animals was approved by the Institutional Animal Care and Use Committee at University of
North Carolina at Chapel Hill.
2.2 Stroma-rich subcutaneous xenograft bladder tumor model
To establish the xenograft model, UMUC3 (5×106) and NIH 3T3 cells (2×106) in 100 µL of
PBS were subcutaneously co-injected with Matrigel (BD Biosciences, CA) at a ratio of 1:1
(v/v) into the right flank of mice. For the standard subcutaneous bladder tumor model, only
UMUC3 cells (5×106) were injected. Tumor volume was measured every three days starting
on day seven after inoculation. The formula: V=(L×W2)/2 was applied to calculate tumor
volume, where V is the tumor volume, L the larger perpendicular diameter and W the
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smaller perpendicular diameter. Tumor growth was normalized to the original volume
calculated on the first day of measurement. Tumor sections collected on day eight for the
two animal models and also those of clinical patients (kindly supplied from Dr. William
Kim, Lineberger Comprehensive Cancer Center, UNC) were stained with hematoxylin and
eosin (H&E), immunofluorescent staining for α-SMA (FITC labeled) and CD31 (Alexa
Fluor 647 labeled). For immunofluorescence, slides were deparaffinized with xylene and a
graded alcohol series. After antigen retrieval, sections were blocked with 10% goat serum
and then incubated with polycolonal rabbit anti-α-SMA antibody (Abcam, Cambridge, MA,
USA) and anti-CD31 (BD Biosciences, CA, USA) at 1:100 dilution overnight at 4 °C.
Immunocomplexes were visualized with the corresponding FITC-labeled and Alexa Fluor
647 secondary antibody at a 1:1000 and 1:100 dilution respectively for 1 h at room
temperature in the dark. Slides were rinsed with PBS and cover-slipped with Vectashield
containing DAPI (Vector laboratories, Burlingame, CA). Digital images were acquired by
an Eclipse Ti-U inverted microscope (Nikon Corp., Tokyo, Japan) 20× magnification and
quantitatively analyzed on Image J (National Institutes of Health).
2.3 In vitro cell viability of free GMP and Cisplatin on UMUC3 cells and analysis of
synergistic effects of free drug combinations
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay was conducted
to evaluate in vitro viability of free GMP, Cisplatin and their combinations. Briefly, cells
were seeded in 96-well plates at a density of 3,000 cells per well 24 h prior to drug
treatment. Subsequently, cells were treated with free drugs and drug combination with
various molar ratio at a series of dilutions in full medium. Following 48 h treatment, 20 µL
MTT (5 mg/mL) reagent was added for an additional 4 h incubation at 37 °C. The medium
was discarded, the formed formazan salt was dissolved in 150 µL of DMSO and absorbance
was read at 570 nm using a multidetection microplate reader (Plate CHAMELEON™ V-
Hidex). Cell survival rates were calculated as normalized to control untreated wells. Each
concentration was tested in four wells and data presented in means±standard error means
(SD). The mean drug concentration required for 50% growth inhibition (IC50) was
determined using CompuSyn software (Version 1.0, Combo-Syn Inc., U.S.) using the
median effect equation: Fa=[1+(IC50/D)m]−1, where Fa is the fraction of affected cells, D is
drug concentration and m is the Hill slope.
Combination Index (CI) Analysis of free drug combination based on the Chou and Talalay
method [18] was performed using CompuSyn software. Briefly, for each level of Fa the CI
values for GMP and Cisplatin combinations were calculated according to the following
equation: CI=(D)1/(Dx)1+(D)2/(Dx)2, where (D)1 and (D)2 are the concentrations of each
drug in the combination resulting in Fa×100% growth inhibition, and (Dx)1 and (Dx)2 are
the concentrations of the drugs alone resulting in Fa×100% growth inhibition. CI values for
drug combinations were plotted as a function of Fa. CI values less than 1 or more than 1
demonstrate synergism or antagonism of drug combinations, respectively. The CI values
between Fa=0.2 and Fa=0.8 are considered valid [19].
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2.4 Tumor accumulation of GMP and Cisplatin in established animal model
To measure tumor accumulation of Combo Free and Combo NP, animals were randomly
divided into two groups (n=6) and intravenously injected with free GMP containing a tiny
fraction of 3H-Labeled free cytidine monophosphate, which is believed to have the similar
pharmacokinetic profile as GMP [16] and Cisplatin (Combo Free) and Combo NP at a dose
of 16 mg/kg and 1.6 mg/kg respectively. Three mice from each group were sacrificed at
each predestinate time point, and approximately 45 mg of blood was withdrawn using the
tail bleeding method. Tumor uptake of GMP and Cisplatin was expressed as the percentage
of the injected dose per gram tumor. For measurement of GMP, 10 to 20 mg of blood was
immediately mixed with 10× NCS® II Tissue Solubilizer (Amersham Biosciences, Inc) and
digested at 60°C overnight. Three hundred µL of hydrogen peroxide (30% in water, Fisher)
was added to the samples and vortexed to bleach the blood color, and then the sample was
mixed with 4 mL scintillation cocktail (Fisher Inc). The 3H radioactivity in the blood
samples was counted using a liquid scintillation analyzer (TRI-CARB 2900 TR, Packard
Bioscience Co.). For the measurement of Cisplatin, approximately 30 mg of blood was
digested with 400 µL 60% nitric acid (Acros Organic) at 70°C overnight and measured by
Inductively Coupled Plasma-Mass Spectroscopy (ICP-MS, NexIONTM 300, Perkin Elmer
Inc).
2.5 Anti-tumor efficacy in stroma-rich xenograft bladder tumor model
On day seven after implantation, mice were randomized by completely randomized design
using a random number table into seven groups (n=5) as follows: Saline (Control group),
free GMP (GMP Free), free Cisplatin (Cisplatin Free), combination of free GMP and
Cisplatin (Combo Free), GMP NP, Cisplatin NP and combination of GMP NP and Cisplatin
NP (Combo NP). For combination of free drugs or nanoparticles, free drugs or nanoparticles
were mixed right before injection. Once they are mixed, the mixture was injected
intravenously. IV injections were performed every three days for a total of 3 injections with
the GMP dose at 16 mg/kg and Cisplatin at 1.6 mg/kg. Tumor volume was measured every
three days using the aforementioned method. Body weight was also recorded. Mice were
sacrificed two days after the last injection by CO2 asphyxiation and tumors were excised. A
portion of the tumor was fixed in 10% formalin and paraffin-embedded sectioned for H&E
staining, TUNEL assay, and α-SMA immunofluorescence by an operator blinded to the
treatment groups.
2.6 In vivo toxicity analysis
After three daily injections, blood was collected from the venous plexus of the eye and
centrifuged at 4,000 rpm for 5 min. Serum alanine aminotransferase (ALT), aspartate
aminotransferase (AST), blood urea nitrogen (BUN) and creatinine levels were assayed as
indicators of hepatic and renal function. Organs (heart, liver, spleen, lung, kidney) were
fixed and sectioned for H&E staining.
2.7 Tissue analysis
Tumor sections were stained for TUNEL assays as recommended by the manufacturer
(Promega, Madison, WI). DAPI mounting medium was dropped on the sections for nuclear
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staining. Apoptosis was also determined by H&E staining. Tumors were also prepared for
α-SMA immunofluorescence (FITC label). Images were acquired by an Eclipse Ti-U
inverted microscope (Nikon Corp., Tokyo, Japan) at 20× magnification and analyzed on
Image J (National Institutes of Health).
2.8 TAF-targeting efficacy in stroma-rich xenograft bladder tumor model
Mice with 200 mm3 tumors were treated with a single dose of Combo NP (GMP 16 mg/kg,
Cisplatin 1.6 mg/kg) (n=24). Every 24 hours, mice were sacrificed. Tumors were excised
and sectioned for α-SMA (Alaxa Fluor 647)/TUNEL immunofluorescence double staining
and Masson’s trichrome (Sigma, USA).
2.9 Analysis of tumor permeability
Drug permeability in the tumor was evaluated by Evans Blue assay [20]. Tumor-bearing
mice were randomized into three groups (n=3) as follows: Control group, Combo Free and
Combo NP. Single intravenous injection was performed for each treatment with the GMP
dose at 16 mg/kg and Cisplatin at 1.6 mg/kg. Twenty-four hours later, 100 mg/kg of Evans
Blue (10 mg/ml in 0.9% NaCl) was intravenously injected. After 30 min, mice were
sacrificed and blood and tumor tissue were homogenized in a 0.1% sodium sulfate/acetone
mixture (7:3 v/v) at a ratio of 1:9. Samples were maintained at ambient temperature in the
dark overnight and then centrifuged at 1,000 g for 5 min. Supernatants were used to
determine absorbance at 620 nm. The amount of Evans Blue in tumor tissue was expressed
as µg/g tissue.
2.10 Statistical analysis
Results were expressed as a mean±standard deviation (S.D.). Student’s t-test and one-way
analysis of variance (ANOVA) test were used to evaluate statistical significance. A p value
of p<0.05 was considered to indicate statistical significance.
3. Results and discussion
3.1. Characterization of GMP NP and Cisplatin NP
The dioleoylphosphatydic acid (DOPA) was employed as a pre-coating reagent for the nano-
sized CaP cores. The lipid coating prevents the core from aggregation during the centrifugal
separation step and makes it soluble in chloroform. The DOPA layer coating CaP core
served as the inner leaflet lipid and a variety of lipids for the outer leaflet could simply be
added into the CaP core solution in chloroform. The choice of the asymmetric outer lipids
plays an important role in the pharmacokinetics and tissue distribution of the final
nanoparticles [21]. Asymmetric lipid bilayer-modified nanoparticles for GMP and Cisplatin
were prepared as previously reported [16,17]. Particles with a core-shell shape were
44.5±0.2 nm and 40.6±0.2 nm for GMP NP and Cisplatin NP, respectively. Particles
exhibited high entrapment efficiency at around 49.5% and 44%, and zeta potential of
11.5±0.6 mV and 5.6 ±0.3 mV for GMP NP and Cisplatin NP, respectively. The drug
loading was 23±2 wt % (n=3) and 82±5 wt % (n=3) for GMP NP and Cisplatin NP,
respectively (Fig. S1).
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3.2. Histopathology for stroma-rich subcutaneous xenograft bladder tumor model
Xenografts with UMUC3 and/or NIH 3T3 cells and patient tumor sections were stained with
H&E and for α-SMA (FITC labeled). Our tumor model was enriched with stroma structure
(H&E) and α-SMA positive cells (17.5±3.2%, UMUC3/NIH 3T3) compared to the common
subcutaneous bladder model with injection of UMUC3 cells alone (1.8±0.6%, UMUC3),
and more closely resembles human bladder tumor structure (14.8±2.1%, Patient) (Fig. 1A).
Alpha-SMA-positive fibroblasts co-located with CD31-positive blood vessel endothelial
cells in our established tumor model (Fig. 1B). The stroma-rich tumor (co-injection with
UMUC3 and NIH 3T3 cells) grew more rapidly (Fig. 1C).
No tumor growth was observed if only NIH 3T3 cells were inoculated. Therefore, such a
stroma-rich tumor closely mimics the structure of human bladder cancer isolates, which
should enable us to better understand the synergistic effect of Combo NP on tumor
inhibition and TAF-targeting effect.
3.3. Synergistic effect induced by tumor accumulation of GMP NP and Cisplatin NP
Gemcitabine has been reported to affect the expression of key proteins involved in
nucleotide excision repair (NER) and mismatch repair (MMR), thereby inhibiting repair of
DNA damage caused by Cisplatin [22]. Synergy between gemcitabine and Cisplatin might
be related to the reduced DNA repair of intra-strand and possibly inter-strand cross-links of
Cisplatin [23]. In vitro toxicity analysis of combined GMP and Cisplatin was performed
after 48 h treatment of UMUC3 cells (Fig. 2). The combination index (CI) was calculated
using a series of molar ratios and amounts of GMP and Cisplatin. CI values were analyzed
according to Chou and Talalay [18] using CompuSyn software (ComboSyn, Inc., Paramus,
NJ, USA). The CI fell between 0.1 and 0.3 over a broad range of drug ratios from the CI vs
Fa plot (Fig. 2B). Synergy, as indicated by a CI<1, therefore, is assumed to be induced over
a wide range of free drug ratios. Within the range of drug ratios, the synergistic effect of
GMP and Cisplatin at a molar ratio of 10 to 1, not only as free drugs but also in
nanoparticles, was further affirmed by in vitro cytotoxicity study of GMP NP, Cisplatin NP,
and Combo NP (Fig. S2). The combination of GMP NP and Cisplatin NP (molar ratio of
10:1) was indicated to exhibit better performance than single nanoparticles alone over a
range of concentrations with the lowest IC50 and small CI value under one. According to the
in vitro data for free drugs and nanoparticles, we apply the combination of GMP NP and
Cisplatin NP at synergistic ratio for further in vivo experiments.
Next, we investigated the synergistic effect of Combo NP and Combo Free in vivo. The
resulting pharmacokinetics (Fig. S3) suggests that Combo NP provides advantages over
Combo Free. About 40 to 45% of the GMP NP were retained in the blood circulation 2 h
after bolus administration, while the free GMP was rapidly cleared within 20 min. AUC and
half-life of Cisplatin NP were 1.4 to 1.7 times higher than that of Cisplatin Free, for which
more than 80% had been cleared after the first 20 min. Incorporation of GMP and Cisplatin
in lipid bilayer coated nanoparticles modified with hydrophilic polyethylene glycol
increased the drug retention in the circulation and reduced the drug clearance which is
consistent with our previous pharmacokinetic studies [16]. However, there is significant
discrepancy in the PK profile of GMP NP and Cisplatin NP. One explanation for the
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difference is that GMP NP with highly positive charges (11.5 mV) are more likely to bind
with serum proteins, leading to longer circulation in the system but lower tissue distribution;
however, Cisplatin NP with relatively neutral charges (5.6 mV) worked in the opposite way.
Moreover, Cisplatin NP produced a slightly higher accumulation in tumor than GMP NP
after a single injection. Both nanoparticles showed significantly higher tumor accumulation
(more than 10% of injected dose per gram remained in the tumor 10 h post injection) than
the free drugs (less than 2% of injected dose per gram left 10 h post injection) (Fig. 2C).
One possible reason is the phenomenon known as enhanced permeability and retention
(EPR). The vasculature of tumors is comprised of poorly aligned and defective endothelial
cells lacking innervation [24,25]. Nanoparticle formulations can increase tumor
accumulation through the EPR effect and with a specific targeting ligand can enhance tumor
cell uptake through a receptor mediated pathway.
The ratio of GMP to Cisplatin (mol: mol) in tumor after Combo NP injection, which is in the
wide synergistic range of free drugs (Fig. 2B) was 8.35:1, and 6.75:1 at 5 h and 10 h after
injection (Fig. 2C); therefore, a synergistic effect took place. When taken together and
incorporated into nanoparticles, GMP and Cisplatin exhibited increased drug retention in the
circulation and enhanced tumor accumulation without altering the synergy. This may result
in more potent anti-tumor effects and reduced side effects [26,27].
3.4. Anti-tumor effect of combined therapy
Here, we report the potent anti-tumor efficacy of the Combo NP in our stroma-rich bladder
tumor model at a dose of 16 mg/kg for GMP and 1.6 mg/kg for Cisplatin. We first
determined whether Combo NP can exhibit synergistic anti-tumor effects without significant
adverse effects (Fig. 3).
When treatment began on day seven after inoculation, free Cisplatin (1.6 mg/kg)
monotherapy showed little anti-tumor effect, with Cisplatin NP being more effective than
free drug (p<0.05). Tumor growth was delayed significantly in mice treated with free GMP
and GMP NP compared to the control group after multiple doses. In comparison, Combo NP
treated tumors had significantly smaller volume than the other six groups at the end of the
experiment, showing growth of only 0.3 fold more than the day one tumor volume. No
weight loss was observed in any treatment group, indicating that the treatment was well
tolerated (data not shown). The enhanced tumor growth inhibition exhibited by
nanoparticles should be attributed to the endocytosis mediated by the sigma receptors and
EPR effect [28], which is also indicated by the tumor accumulation study aforementioned.
Nanoparticle formulation with specific targeting ligand can increase tumor accumulation
through EPR effect and enhanced tumor cell uptake through receptor-mediated pathway.
Furthermore, in vivo maintenance of drug ratios shown to be synergistic in vitro was proven
to provide increased efficacy in preclinical tumor models [29]. Therefore, the synergistic
effect proven by the tumor accumulation study (Fig. 2), enabled the Combo NP to show the
most outstanding effect on tumor growth inhibition in comparison with GMP NP and
Cisplatin NP alone.
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3.5. In vivo toxicity
To test the toxicity of combined GMP NP and Cisplatin NP, blood was obtained for
hematological analysis and histopathology of organs was evaluated by H&E staining.
Gemcitabine and Cisplatin are notable for their potential hepatic and renal toxicities
respectively. In our toxicity studies, AST increased slightly in Combo NP group, but
remained within the normal range (Table 1) [16]. No noticeable histological changes were
seen in H&E-stained tissue sections of heart, liver, spleen, lung and kidney (Fig. S4). There
were no noticeable changes between the control and Combo NP group, which showed no
evidence of organ toxicity. These findings suggest the potential application of nanoparticles
in clinic.
3.6. Combo NP triggers cell apoptosis and inhibits fibroblasts growth
Stroma-rich tumor-bearing mice were sacrificed two days after the final injection and the
tumors were sectioned for TUNEL assay and α-SMA immunohistochemistry. In the
TUNEL assay (Fig. 4A), the Combo NP exhibited the most effective killing effects and
induced a 16.1 fold higher amount of apoptotic cells compared with the control group. This
was more potent than the Combo Free treatment group, which showed 55.5% less apoptosis
than that of the Combo NP. There was no significant difference among Combo Free, GMP
NP and Cisplatin NP groups (p>0.05). Cisplatin Free treatment had limited ability to induce
apoptosis in tumor cells. The results indicate the combination of GMP NP and Cisplatin NP
augments the intrinsic cytotoxicity. This finding is consistent with data in Figure 3 that the
Combo NP exerts synergistic anti-tumor effects.
Meanwhile, Combo NP not only elicited an apoptosis-inducing effect on carcinoma cells,
but also changed the number of α-SMA-positive fibroblasts in the tumor extracellular
matrix. To assay for this change, we used immunofluorescence to measure the percentage of
α-SMA-positive fibroblasts in the normal untreated tumor and in tumors treated with
different preparations (Fig. 4). α-SMA was significantly decreased in the Combo NP group
compared to the untreated group (0.7±0.3% vs. 17.6±3.2%, percentage of positive-stained
cells, p<0.05). The fibroblasts expression after Combo NP treatment was 89.7%, 87.2% and
94.3% lower than that after GMP Combo NP 58.3±6.8 252±10.3 5.3±0.4 0.2±0.1 NP,
Cisplatin NP, and Combo Free treatment, respectively (p<0.05). Those results suggest the
importance of the combination of GMP NP and Cisplatin NP for in vivo efficacy. H&E
staining also indicated that the Combo NP caused the most severe necrosis in the tumor.
3.7. Combo NP depletes TAFs in the tumor, modifies collagen deposition
Taking advantage of the stroma-rich animal model, the interaction of TAFs and the
combined drugs was also investigated. The effect of a single Combo NP injection treatment
on fibroblasts and tumor cells in the stroma-rich bladder tumor model was investigated from
day one to day seven after treatment. Day 0 before treatment was also investigated.
Fig. 5A–C present the double staining for TUNEL and α-SMA and the quantitative results.
Firstly, 4.9% of cells were induced to undergo apoptosis one day after Combo NP injection,
among which 56.6% apoptotic cells were α-SMA-positive. This suggests that the fibroblasts
have a greater tendency to be killed compared to tumor cells. From day one to day two, the
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apoptotic fibroblasts in total apoptotic cells increased dramatically resulting in more than
60% apoptotic fibroblasts. The apoptotic cells in fibroblasts reached 87.2% on day four,
which was 45% higher than that in carcinoma cells. The results indicate that the apoptosis of
fibroblasts not only began before that of carcinoma cells but also substantially resulted in
fibroblast depletion. By the last two days, the killing effect of the Combo NP was reduced
and fewer cells were apoptotic, with the increasing number of α-SMA-positive fibroblasts.
Therefore, the apoptotic fibroblast (%) in total fibroblast was significantly decreased to
nearly 1%. Secondly, the collagen on day four became 14.9% of the original collagen
present on day 0, a value also different from that of day three. This shows that the killing
effect of Combo NP on TAFs in the first three days resulted in the decreased deposition of
collagen on day four. Collage deposition showed an increasing trend starting on day five
(Fig. 5D).
As it is shown in Fig. 4, Combo Free, GMP NP, and Cisplatin NP exhibited partial efficacy
in reducing fibroblasts, but Combo NP showed the fewest α-SMA positive cells and induced
the most tumor cell apoptosis compared to all the treatment groups (p<0.05). The data
suggest that the combination therapy may have a TAF-targeted effect by inducing cell
apoptosis with a strong inhibition of stroma cell proliferation. Under that hypothesis, we
administered a single injection of Combo NP and detected the apoptotic fibroblasts every 24
h after injection. The larger amount of apoptotic fibroblasts compared to apoptotic tumor
cells and collagen re-deposition indicated that tumor stroma was the target for the Combo
NP and tumor cell killing could be the secondary role of the Combo NP. The TAF-targeting
effect could be interpreted by the following two explanations: (1) the myofibroblasts were
much more sensitive to the Combo NP than that of bladder carcinoma cells. (2) Tumor
blood vessels are reported to be located in the stroma [30,31] and Fig. 1B also indicates that
some CD31-positive cells are co-located with α-SMA-positive fibroblasts. Our explanation
could be that Combo NP, once delivered through tumor vessels and transferred from the
vessel wall with high permeability through extra cellular matrix to the tumor cells will
exhibit killing effect on the TAFs as the first target instead of tumor cells since the TAFs are
distributed along the vessel or near the vessel.
3.8. Tumor vessel permeability
Passive targeting of liposomal formulations is mediated mainly by the enhanced vascular
permeability of tumor vessels. To evaluate vascular permeability after Combo Free and
Combo NP treatment, tumor bearing mice were intravenously injected with Evans Blue,
which binds to serum albumin and tends to accumulate in tissues with leaky vasculature
[20]. Vascular permeability was found to be nearly 21.3 and 2.7 times higher in the Combo
NP group than in the Control and Combo Free groups, respectively (Fig. 6). Besides the
increasing transport through vasculature, the enhanced intratumoral uptake of Evans Blue
might also be contributed to tumor priming effect by substantial apoptosis caused by
pretreatment with single injection of Combo NP (Fig. 5). This could reduce tumor cell
density, expend the interstitial space and then promote the penetration into three-
dimensional tumor histocultures [32,33]. Further investigation is desired for the mechanism
of greater tumor uptake of Evans Blue.
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The more pronounced accumulation from Combo NP could be attributed to the synergistic
effect of GMP NP and Cisplatin NP on the tumor blood vessels: (1) Combo NP could
significantly reduce the expression of vascular endothelial growth factor (VEGF) (Fig. S5),
which is an important mediator of tumor angiogenesis, and enhance the extent of tumor
vasculature abnormalities, which impairs the tumor growth [34–36]. This finding is
consistent with previous result that Combo NP exerts higher tumor inhibition (Fig. 3); (2)
Fig. 5 indicates that because of their sensitivity or proximity to tumor blood vessels, the
TAFs will be first killed by nanoparticles distributed in the stoma and the collagen in stroma
will be depleted. This depleting effect could be helpful for better distribution of antitumor
compounds in the tumor area which would not otherwise access the tumor cells [37], and
enhance the total drug tumor accumulation and transport to carcinoma cells.
4. Conclusions
In this study, anti-tumor effects of Combo NP were investigated in a stroma-rich xenograft
bladder cancer model. GMP and Cisplatin accumulated in treated tumor tissue at a molar
ratio and concentration expected to have synergistic anti-tumor effects. Combo NP’s ability
to inhibit tumor growth was enhanced relative to Combo Free with no obvious toxicity. The
effectiveness of Combo NP could be attributed to its effect on both carcinoma cells and
TAFs. The anti-tumor activity of Combo NP may result from the combined effects of TAFs
depletion with alterations in collagen deposition and increased uptake of chemotherapeutic
drugs by the tumor and apoptosis of carcinoma cells. Since the standard first line
chemotherapy for muscle invasive bladder cancer is now gemcitabine plus Cisplatin [38,39],
the result of our study suggest that Combo NPs could be tested clinically to replace free drug
combination.
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Histopathology for tumor formed by injection of UMUC3 cells (20×) without or with NIH 3T3 cells and from patient section
(A); the expression of α-SMA, CD31 and merge (α-SMA: green; CD31: red; co-located: yellow) (B) in tumor formed by
coinjection of UMUC3 with NIH 3T3 cells; tumor growth curves of different inoculations were charted since the tumor volume
reached 200 mm3 (C). Tumor growth increment was presented by normalizing to the original volume on the 1st day of
measurement (Vt/V0) (n=5).
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Cytotoxicity study of free GMP, Cisplatin and Combo Free at variable molar ratios (A) with the corresponding CI vs Fa plot
(B), and tumor accumulation of GMP NP and GMP Free (Red bars), and Cisplatin NP and Cisplatin Free (Blue bars) at 5 h and
10 h after administration (n=3) (C).
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Tumor growth inhibition effects of different formulations on stroma-rich tumor bearing mice. GMP Free, Cisplatin Free, Combo
Free, GMP NP, Cisplatin NP and Combo NP were administered intravenously every third day for a total of three injections as
indicated by arrows. Data are mean±S.D. Statistics are as follows: * p<0.05 vs. Control; #p<0.05 vs. Combo NP; there is no
significant difference among groups marked with “#”, n=5.
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Effects of different treatments on the induction of apoptosis in tumor, the inhibition of fibroblast growth and tumor tissue H&E
stain (20×) (A) and quantitative results expressed as the percentage of total cell number (B). * p<0.05 vs. Control; # p<0.05 vs.
Combo NP.
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Immunofluorescence double staining for SMA-positive fibroblasts (red), TUNEL (green) and apoptotic fibroblasts (yellow) (A);
quantitative results for TUNEL-positive cells and α-SMA-positive fibroblasts (B); quantitative results for apoptotic fibroblasts
expressed as the percentage of total apoptotic cells and fibroblasts (C); quantitative results for collagen expressed by the area
(%) (D); Masson’s trichrome stain for collagen (blue) (E) in tumor-bearing mice treated with a single injection of the Combo
NP. Tumors were excised on Day 0 and every 24 h for 7 days for analysis and expressed as 0 (Day 0) to 7 (Day 7) in the image.
* p <0.05.
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Evans Blue staining of mice to determine tumor vessel leakiness. Single intravenous injection was performed for each treatment
with the GMP dose at 16 mg/kg and Cisplatin at 1.6 mg/kg. Twenty-four hours later, mice were injected with 100 mg/kg of
Evans blue. After 30 min, the mice were sacrificed, and samples from the tumors were removed. The concentration of Evans
Blue was then determined spectrophotometrically. Results are shown as the mean weight of Evans Blue per gram tissue. * p
<0.05 vs. Control; # p<0.05 vs. Combo NP. n=3.
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Table 1
Effect of GMP NP, Cisplatin NP, Combo Free and Combo NP on serum ALT, AST, BUN and creatinine
levels




Control 60.7±15.3 191±13.7 5.2±0.4 0.2
GMP NP 59.6±8.7 98±11.6 6.4±1.6 0.2±0.1
Cisplatin NP 66.3±1.5 171±8.2 7.2±1.2 0.2
Combo Free 44.3±10.2 230±8.9 5.7 0.2
Combo NP 58.3±6.8 252±10.3 5.3±0.4 0.2±0.1
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